Angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
== Chemistry == The chemical structure of ACD856 has not yet been disclosed as of 2024, but the structure of its predecessor ponazuril (ACD855) is known and both ponazuril and ACD856 have been described as triazinetriones.
==== Nanoreactors ==== Enzyme-catalyzed reactions can be performed at higher temperatures using enzyme-immobilized nanoparticles, in which the presence of multiple proteins at the nanoparticle surface facilitates the retention of water molecules limiting the denaturation of the attached proteins. After modification with poly(amide), protein activity could remain unchanged over 500 min at 50 °C, while the half-life time of the native lipase at 50 °C is only 30 min in aqueous solution. Immobilized enzymes on nanoparticles can significantly improve the efficiency of enzyme reactions by increasing tolerance to a wider range of experimental conditions without significantly reducing biological activity. Besides, polymer-protein particles are reported to control the activity of proteins and compartmentalize different enzymes to perform multi-step reactions.
Prevent or treat dehydration Prevent or treat low blood sugar Prevent or treat low body temperature Prevent or treat infection; Correct electrolyte imbalances Correct micronutrient deficiencies Start feeding cautiously Achieve catch-up growth Provide psychological support Prepare for discharge and follow-up after recovery
By 1 June, Richard had conquered the whole island. His exploit was well publicized and contributed to his reputation; he also derived significant financial gains from the conquest of the island. Richard left for Acre on 5 June, with his allies. Before his departure, he named two of his Norman generals, Richard de Camville and Robert de Thornham, as governors of Cyprus. While in Limassol, Richard the Lion-Heart married Berengaria of Navarre, first-born daughter of King Sancho VI of Navarre. The wedding was held on 12 May 1191 at the Chapel of St. George and it was attended by Richard's sister Joan, whom he had brought from Sicily. The marriage was celebrated with great pomp and splendor. Among other grand ceremonies was a double coronation: Richard caused himself to be crowned King of Cyprus, and Berengaria Queen of England and Queen of Cyprus as well.
Sources: en.wikipedia.org
==== Antidepressants ==== Some antidepressants have hypnotic and/or sedative effects. These include the serotonin antagonist and reuptake inhibitor (SARI) trazodone, tricyclic antidepressants (TCAs) such as amitriptyline, doxepin, and trimipramine, and tetracyclic antidepressants (TeCAs) like mirtazapine and mianserin. These agents produce their hypnotic and sedative effects via multiple mechanisms of action that may include histamine H1 receptor antagonism, serotonin 5-HT2A receptor antagonism, and α1-adrenergic receptor antagonism. Some hypnotic antidepressants, such as trazodone and mirtazapine, have been shown to enhance slow wave sleep, which may be due to serotonin 5-HT2A receptor antagonism.
== Chemoenzymatic strategies == There is no general biochemical solution for macrocyclization of a peptide chain. Isolated tyrocidine (Tyc) TE domains can be used to cyclize chemically derived peptidyl-thioester substrates, providing a powerful route to new cyclic compounds. In order for this macrocyclization to occur, the peptide chain must be activated at its C-terminus with an N-acetylcysteamine (SNAC) leaving group. An alanine scan through the 10 positions of tyrocidine shows that only the D-Phe and L-Orn are required for sufficient cyclization.
However, unlike tramadol, tapentadol exerts minimal influence on serotonin reuptake and is approximately 2–3 times more potent as an opioid. Tapentadol also lacks active metabolites, which distinguishes it from tramadol and may contribute to a more predictable pharmacokinetic profile.
Efficacy was evaluated in KEYNOTE-A18 (NCT04221945), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 1060 participants with cervical cancer who had not previously received definitive surgery, radiation, or systemic therapy. The trial included 596 participants with FIGO 2014 Stage III-IVA disease and 462 participants with FIGO 2014 Stage IB2-IIB, node-positive disease. In June 2024, the US FDA approved pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial carcinoma. Efficacy was evaluated in KEYNOTE-868/NRG-GY018 (NCT03914612), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 810 participants with advanced or recurrent endometrial carcinoma. The trial included two separate cohorts based on mismatch repair status: 222 participants in the mismatch repair deficient cohort, and 588 participants in the mismatch repair proficient cohort. Efficacy was evaluated in KEYNOTE-905/EV-303 (NCT03924895), an open-label, randomized, multi-center, active-controlled trial in 344 participants with previously untreated muscle invasive bladder cancer who were candidates for radical cystectomy with pelvic lymph node dissection but were ineligible for or declined cisplatin-based chemotherapy.
=== Regional === Rabbi Eliyahu Zini, the uncle of Shin Bet Chief David Zini, criticized the agreement with the Lebanese government, asserting, "all of Lebanon belongs to us." He questioned Israeli ministers, asking, "Are you normal? You are giving up the inheritance of our ancestors on what basis?". Hezbollah expressed conditional acceptance of the ceasefire, warning that Israeli military presence in Lebanon would justify continued resistance. Lebanese political figures advised civilians to delay returning to affected areas until the terms and stability of the agreement became clearer.
Sources: en.wikipedia.org
== See also == Drilosphere, the part of the soil influenced by earthworm secretions and castings The Formation of Vegetable Mould through the Action of Worms, an 1881 book by Charles Darwin Soil life Vermicompost Vermifilter Vermifilter toilet Worm charming
The Trails of Cold Steel arc follows Rean Schwarzer and Class VII, a specialized group of students attending Thors Military Academy in the Erebonian Empire. The first game, Trails of Cold Steel was released for the PlayStation 3 and PlayStation Vita in Japan in 2013. Trails of Cold Steel II is a direct continuation of the first game and was released for the PlayStation 3 and Vita in 2014. The third and fourth games, Trails of Cold Steel III and IV, follow Rean in his new role as an instructor of a new Class VII at a branch campus of Thors. Cold Steel III was released for the PlayStation 4 (PS4) in Japan in 2017, while Cold Steel IV was released in the following year. A fifth game, Trails into Reverie, was released in 2020 and acts as an epilogue to both the Crossbell and Erebonia arcs and follows Rean, Lloyd, and a masked character known as C. English versions of Cold Steel and Cold Steel II were released by Xseed Games in 2015 and 2016, respectively. NIS America released Cold Steel III in 2019, IV in 2020, and Trails into Reverie in 2023. A box set containing all five games was released in Japan for the PS4 in July 2022.
=== Positions on trans identity, accusations of transphobia and connections to the far-right === On January 22, 2020, after a collage was posted in the city of Montpellier calling for the inclusion of trans women in the feminist movement with the slogan "sisters not cisTERF" (a pun on "cis", i.e. not trans, and "TERF", meaning "transgender-exclusionary radical feminist"), she commented she felt trans activism had become too important in the collage movement and within feminism on Twitter. She stated in particular that being a woman is a question of biology and that the activism of trans women was insulting and reduced women to a set of patriarchal stereotypes such as makeup and clothes. She denied trans women's womanhood, stating: "Throughout time, men have tried to silence women by silencing their revolts. Today, they do it from the inside by infiltrating our struggles". She refuses trans-inclusive language such as "people with vulvas". Her positions have led to her being considered a "TERF" by intersectional feminists. Following these statements, the Instagram account Collages Féminicides Paris distanced itself from her comments: "Discrimination has always been condemned […]. We're talking about the exclusion of a part of women from the struggle; transphobia is not a debate." She became increasingly marginalized in the collage movement, months after leaving its leadership. She was the subject of numerous insults on social networks, so much so that the collective reacted and specified that it repudiates any "killing rhetoric".
The volatilities for niobium and tantalum were similar within error limits, but dubnium appeared to be significantly less volatile. It was postulated that traces of oxygen in the system might have led to formation of DbOBr3, which was predicted to be less volatile than DbBr5. Later experiments in 1996 showed that group 5 chlorides were more volatile than the corresponding bromides, with the exception of tantalum, presumably due to formation of TaOCl3. Later volatility studies of chlorides of dubnium and niobium as a function of controlled partial pressures of oxygen showed that formation of oxychlorides and general volatility are dependent on concentrations of oxygen. The oxychlorides were shown to be less volatile than the chlorides. In 2004–05, researchers from Dubna and Livermore identified a new dubnium isotope, 268Db, as a fivefold alpha decay product of the newly created element 115. This new isotope proved to be long-lived enough to allow further chemical experimentation, with a half-life of over a day. In the 2004 experiment, a thin layer with dubnium was removed from the surface of the target and dissolved in aqua regia with tracers and a lanthanum carrier, from which various +3, +4, and +5 species were precipitated on adding ammonium hydroxide. The precipitate was washed and dissolved in hydrochloric acid, where it converted to nitrate form and was then dried on a film and counted.
=== Joint operation against Niño Guerrero === In June 2026, a military operation was carried to kill Héctor Rusthenford Guerrero Flores, known as Niño Guerrero, the leader of the Venezuelan criminal gang Tren de Aragua. US president Donald Trump announced that Guerrero was killed in a airstrike on 12 June in Venezuela conducted in coordination with Venezuelan authorities. Venezuelan officials confirmed their participation in the operation.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.